Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has, not surprisingly, returned. To cope, yes, we are brewing cups of stimulation — maple bourbon is our choice today — and we invite you to join us. Meanwhile, we are pleased to celebrate STAT’s fifth birthday. Have a slice of virtual cake on us. And now, time to get cracking. Here are some tidbits to help you along, Have a smashing day, and do stay in touch. …

A Covid-19 vaccine being developed by the University of Oxford and AstraZeneca (AZN) produced an immune response in both young and old adults, and also triggered lower adverse responses among the elderly, Reuters explains. Immunogenicity blood tests carried out on a subset of older participants echo data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55. Details of the finding are expected to be published shortly in a clinical journal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!